← Eichor
Study identifier: NCT06597591 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Virtual Reality Training for Inhibitory Control in Neurocognitive Disorders

Condition: Cognitive Disorder  ·  Sponsor: Centre Hospitalier Universitaire de Nice

PhaseNA
Planned participants48
Who can joinAll sexes, 60 Years to no upper limit
Healthy volunteersNo

About this study

Executive function disorders, such as inhibitory control (IC) difficulties, are very common in older adults with neurocognitive disorders (NCD). Management of these disorders is possible using traditional tools and tools based on new technologies, such as serious games and virtual reality (VR). However, today, few immersive tools exist that are specifically focused on IC training. The present study aims to evaluate the acceptability of an immersive application focused on IC in 48 patients with neurocognitive disorders. Participants that will test either an immersive (VR-headset) or a non-immersive (tablet) version of the application for 4 weeks, twice a week, and fill-in acceptability related questionnaires before, during and after the end of the intervention.

This description comes directly from the study's public registry record.

Talk to the study team

Lemaire Justine  ·  +330492034778  ·  lemaire.j@chu-nice.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de NiceNice, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06597591